Phase I/II Trial of Nanomolecular Liposomal Annamycin in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia-Reference-Cited by-同舟云学术

Phase I/II Trial of Nanomolecular Liposomal Annamycin in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

Published:2013-08 Issue:4 Volume:13 Page:430-434
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Wetzler Meir,Thomas Debora A.,Wang Eunice S.,Shepard Robert,Ford Laurie A.,Heffner Thompson L.,Parekh Samir,Andreeff Michael,O'Brien Susan,Kantarjian Hagop M.

Funder

National Cancer Institute

Szefel Foundation

Roswell Park Cancer Institute

Nancy C. Cully Endowment for Leukemia Research

Leonard S. LuVullo Endowment for Leukemia Research

Callisto Pharmaceuticals

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference16 articles.

1. Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma;DeAngelo;Hematol Oncol Clin North Am,2009

2. FDA approves liposomal vincristine (Marqibo) for rare leukemia;Oncology (Williston Park),2012

3. MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia;Tafuri;Blood,2002

4. Design and tumor targeting of anthracyclines able to overcome multidrug resistance: a double-advantage approach;Priebe;Pharmacol Ther,1993

5. The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines;Consoli;Blood,1996

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nanotheranostics: Clinical Status, Toxicity, Regulatory Consideration, and Future Prospects;Nanotheranostics for Diagnosis and Therapy;2024

2. Re-Exploring the Anthracycline Chemical Space for Better Anti-Cancer Compounds;Journal of Medicinal Chemistry;2023-08-10

3. Multifunctional targetable liposomal drug delivery system in the management of leukemia: Potential, opportunities, and emerging strategies;Life Sciences;2023-07

4. Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies;Journal of Hematology & Oncology;2023-06-23

5. Clinical Trials Involving Chemotherapy-Based Nanocarriers in Cancer Therapy: State of the Art and Future Directions;Cancer Nanotechnology;2022-12-14